Interleukin-10 fails to modulate low shear stress-induced neointimal hyperplasia.
暂无分享,去创建一个
L. Moldawer | T. Huber | R. Minter | C. Ozaki | J. Seeger | J. Rectenwald | Z. Abouhamze | D. La Face | Elizabeth Hutchins | J. Rectenwald | R. Minter | Thomas S. Huber | James M. Seeger | C.Keith Ozaki | C. Ozaki
[1] J. Vermylen,et al. Mouse Carotid Artery Ligation Induces Platelet-Leukocyte–Dependent Luminal Fibrin, Required for Neointima Development , 2001, Circulation research.
[2] L. Moldawer,et al. Extended lung expression and increased tissue localization of viral IL-10 with adenoviral gene therapy. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[3] L. Moldawer,et al. Direct Evidence for Cytokine Involvement in Neointimal Hyperplasia , 2000, Circulation.
[4] D. Rennick,et al. XII. IL-10-deficient (IL-10− / −) mice and intestinal inflammation * , 2000 .
[5] L. Moldawer,et al. ANTICYTOKINE THERAPIES FOR ACUTE INFLAMMATION AND THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: IL‐10 AND ISCHEMIA/REPERFUSION INJURY AS A NEW PARADIGM , 2000, Shock.
[6] M. Ziol,et al. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. , 2000, Circulation.
[7] L. Moldawer,et al. TNF-α Receptor Signaling and IL-10 Gene Therapy Regulate the Innate and Humoral Immune Responses to Recombinant Adenovirus in the Lung1 , 2000, The Journal of Immunology.
[8] M. Territo,et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[9] R. Terkeltaub. IL-10: An "immunologic scalpel" for atherosclerosis? , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[10] M. Bureau,et al. Protective role of interleukin-10 in atherosclerosis. , 1999, Circulation research.
[11] D. Dichek,et al. Adventitial delivery minimizes the proinflammatory effects of adenoviral vectors. , 1999, Journal of vascular surgery.
[12] A. Tedgui,et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[13] S. Opal,et al. Interleukin-10: potential benefits and possible risks in clinical infectious diseases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] E. Keystone,et al. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. , 1998, Rheumatic diseases clinics of North America.
[15] A. Tedgui,et al. Signal transduction of mechanical stresses in the vascular wall. , 1998, Hypertension.
[16] G. Rogler,et al. Cytokines in Inflammatory Bowel Disease , 1998, World Journal of Surgery.
[17] L. Moldawer,et al. Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. , 1998, Journal of applied physiology.
[18] R. McIntyre,et al. Interleukin-10 inhibits human vascular smooth muscle proliferation. , 1998, Journal of molecular and cellular cardiology.
[19] R. Ross,et al. Atherosclerosis is an Inflammatory Disease , 1998 .
[20] V. Lindner,et al. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. , 1997, Circulation.
[21] Amit Kumar,et al. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[22] H. Perlman,et al. Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. , 1997, Circulation.
[23] D. Alarcón-Segovia,et al. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. , 1997, Journal of immunology.
[24] P. Libby,et al. The molecular bases of restenosis. , 1997, Progress in cardiovascular diseases.
[25] L. Moldawer,et al. Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor-dependent murine model of acute visceral ischemia. , 1997, Journal of vascular surgery.
[26] Y. Yazaki,et al. Inflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth-muscle phenotypes in pigs. , 1997, Journal of cardiovascular pharmacology.
[27] J. Banchereau,et al. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. , 1997, Journal of immunology.
[28] P. Hart,et al. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. , 1996, Journal of immunology.
[29] B L Langille,et al. Cellular and molecular biology of vascular remodeling , 1996, Current opinion in lipidology.
[30] S M Schwartz,et al. The intima. Soil for atherosclerosis and restenosis. , 1995, Circulation research.
[31] P. Davies,et al. Flow-mediated endothelial mechanotransduction. , 1995, Physiological reviews.
[32] A. Gotlieb,et al. Expression of tumour necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. , 1995, British heart journal.
[33] F. Graham,et al. Methods for construction of adenovirus vectors , 1995, Molecular biotechnology.
[34] M. Feldmann,et al. Two inhibitors of pro‐inflammatory cytokine release, interleukin‐10 and interleukin‐4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes , 1994, European journal of immunology.
[35] H. Shepard,et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. , 1994, Human gene therapy.
[36] F. Calzetti,et al. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation , 1994, The Journal of experimental medicine.
[37] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[38] P. Davies,et al. Hemodynamic forces and vascular cell communication in arteries. , 1992, Archives of pathology & laboratory medicine.
[39] M. Gimbrone,et al. Vascular endothelium responds to fluid shear stress gradients. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[40] C G Figdor,et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.
[41] T. Mosmann,et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[42] T. Mosmann,et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. , 1990, Science.
[43] B L Langille,et al. Adaptations of carotid arteries of young and mature rabbits to reduced carotid blood flow. , 1989, The American journal of physiology.
[44] P. Libby,et al. Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. , 1989, Journal of immunology.
[45] S. Narula,et al. Immunomodulation of Crohn's disease by interleukin-10. , 1998, Agents and actions. Supplements.
[46] S. V. van Deventer,et al. Immunotherapy of Crohn's disease. , 1998, Mediators of inflammation.
[47] P. Libby,et al. Cytokines Regulate Vascular Functions Related to Stability of the Atherosclerotic Plaque , 1995, Journal of cardiovascular pharmacology.
[48] P. Libby,et al. Cytokines as mediators of vascular pathology. , 1992, Nouvelle revue francaise d'hematologie.